Groundbreaking £21.9M UK Platform Launched to Advance Cancer Immunotherapy 7 Nov 2024
Cancer immunotherapy represents a remarkable advancement in medical science, offering hope for conditions once considered untreatable. While some patients experience life-changing results, a large number face limited success or significant side effects. This is particularly evident with melanoma treatments, where fewer than half of patients benefit from immunotherapy.
To address these disparities, the UK has launched a major programme, MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity), backed by £21.9 million from government and industry funding.
This collaborative effort—bringing together institutions like the Francis Crick Institute and The Royal Marsden NHS Foundation Trust—aims to refine immunotherapy practices, helping patients gain more reliable and personalised outcomes.
At the heart of the MANIFEST programme is a commitment to understand the underlying factors that influence treatment success and side effects.
The project will analyse biomarkers—indicators of how patients may respond to treatment. The aim is to identify those patients most likely to benefit from immunotherapy.
Thousands of samples from patients treated for cancers such as breast, bladder, kidney, and skin cancer will provide insights into tumour genetics, immune cell profiles, and even gut microbiome composition.
Such comprehensive data collection may improve patient selection —and open doors to developing new treatments, such as cell therapies and cancer vaccines.
Cancer research like this demonstrates the importance of a unified approach between healthcare, research, and industry.
The MANIFEST programme promises advancements in patient care, training for future specialists, and potentially significant economic benefits. For more details on the MANIFEST programme, click here.
PharmaMedic’s support of regulatory and medical affairs can provide valuable support to organisations bringing these innovations to patients. Our team is here to help expedite the development and safe delivery of treatments that meet patients’ needs.
Let’s discuss how PharmaMedic can support your goals today.
Email: hello@pharmamedic.co
Phone: +44 (0)207 691 4912